RxDoctor Payments Data

Cassandra Youmans, MD

Cardiovascular Disease · New Orleans, LANPI 1518988534

Payments from drug & device makers

$8,593in general payments, 2019–2025

Across 69 payments — averaging $124.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$7K
  • AbbVie$471
  • Ironshore Pharmaceuticals Inc.$333
  • Jazz Pharmaceuticals Inc.$128
  • Lilly USA, LLC$102
  • Neurocrine Biosciences, Inc.$87
  • plus $225 from 9 others

What the payments were for

  • Consulting fees$4,20049%
  • Travel & lodging$7459%
  • Food & beverage$3,64842%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,593 in reported general payments places this provider in the 70th percentile of 281 cardiovascular disease providers in Louisiana.

See all cardiovascular disease providers in Louisiana

Medicare billing

Part B allowed, 2024
$1,923
Medicare patients
14
Services billed
25

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpclusaSofosbuvir/Velpatasvir16$391,178
MounjaroTirzepatide34$54,474
JardianceEmpagliflozin34$54,456
LinzessLinaclotide42$49,091
OzempicSemaglutide34$40,671
JanuviaSitagliptin Phosphate27$32,080
EliquisApixaban18$26,152
TrulicityDulaglutide24$26,100
VemlidyTenofovir Alafenamide13$18,647
Repatha SureclickEvolocumab31$17,626
Gabapentin67$1,970
Albuterol Sulfate HfaAlbuterol Sulfate58$1,772
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$1,769
Atorvastatin Calcium114$1,069
Fluticasone Propionate60$899

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadEpclusa, Vemlidy$7,247$409,82629 claims
Lilly USA, LLCMounjaro, Trulicity$102$80,57458 claims
AbbVieLinzess$471$49,09142 claims
Novo NordiskOzempic$18$40,67134 claims
PfizerEliquis$37$26,15218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 281 cardiovascular disease providers in Louisiana.

Other cardiovascular disease in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →